We are a biopharmaceutical company operating in China and the US, focusing on innovative CAR-T cell therapies for the treatment of hematoma and solid tumors. Since we began operations in 2014, we have developed a number of new technologies and globally beneficial product pipelines in-house to address the major challenges facing CAR-T cell therapy, such as improving safety, improving the efficacy of solid tumors, and reducing treatment costs. Our product pipeline includes an upgraded version of the all-human BCMACAR-T, the world's only potentially first-of-its-kind Claudin18.2car-T approved for IND clinical trials, and the world's potential first-of-its-kind GPC3CAR-T. For CAR-T cell therapy, we have received a total of 7 IND approvals in China, the US, and Canada, which is currently the highest number of CAR-T companies in China. Under the leadership of a management team composed of experienced academic experts and industry veterans, we have established an integrated cell therapy platform with in-house capabilities covering target discovery, pilot antibody development, clinical research, and commercial-scale production.
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data
No Data